Evidence map›Paper›PMID 39968184›Full record

ArticleMolecular therapy. Methods & clinical development2025

An automated and high-throughput approach for enhanced precision of adenoviral titering.

Paolo Bottega, Manlio Fusciello, Firas Hamdan, Jacopo Chiaro, Salvatore Russo, Federica D'Alessio, Mikaela Grönholm, Vincenzo Cerullo

Abstract read
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Paolo BottegaDepartment of Pharmaceutical Biosciences, University of Helsinki, Faculty of Pharmacy ImmunoViroTherapy Lab, Drug Research Program, Viikinkaari 5E, 00790 Helsinki, Finland.
Manlio FuscielloDepartment of Pharmaceutical Biosciences, University of Helsinki, Faculty of Pharmacy ImmunoViroTherapy Lab, Drug Research Program, Viikinkaari 5E, 00790 Helsinki, Finland.
Firas HamdanDepartment of Pharmaceutical Biosciences, University of Helsinki, Faculty of Pharmacy ImmunoViroTherapy Lab, Drug Research Program, Viikinkaari 5E, 00790 Helsinki, Finland.
Jacopo ChiaroDepartment of Pharmaceutical Biosciences, University of Helsinki, Faculty of Pharmacy ImmunoViroTherapy Lab, Drug Research Program, Viikinkaari 5E, 00790 Helsinki, Finland.
Salvatore RussoDepartment of Pharmaceutical Biosciences, University of Helsinki, Faculty of Pharmacy ImmunoViroTherapy Lab, Drug Research Program, Viikinkaari 5E, 00790 Helsinki, Finland.
Federica D'AlessioDepartment of Pharmaceutical Biosciences, University of Helsinki, Faculty of Pharmacy ImmunoViroTherapy Lab, Drug Research Program, Viikinkaari 5E, 00790 Helsinki, Finland.
Mikaela GrönholmDepartment of Pharmaceutical Biosciences, University of Helsinki, Faculty of Pharmacy ImmunoViroTherapy Lab, Drug Research Program, Viikinkaari 5E, 00790 Helsinki, Finland.
Vincenzo CerulloDepartment of Pharmaceutical Biosciences, University of Helsinki, Faculty of Pharmacy ImmunoViroTherapy Lab, Drug Research Program, Viikinkaari 5E, 00790 Helsinki, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate quantification of viral vectors and vaccines is a crucial step required before any downstream use of virus preparations. The conventional immunocytochemistry-based method of adenovirus quantification has been widely used, but there are many areas for improvement toward accuracy and resource consumption savings to reduce viral miscalculation and wastage of vaccination materials. In this work, a one-step approach is implemented for optimized adenoviral quantification that uses a single antibody coupled with automated, high-throughput image acquisition and subsequent batch analysis. First, cells are infected with the adenovirus of interest and stained using the Hexon protein. Then, multichannel automated image acquisition via the Invitrogen EVOS M7000 Imaging System is performed. Last is an automated large batch analysis of acquired images via the EVOS Analysis Software, accomplished via precise training of the software allowing for virus infection quantification and additional parameters (counts, circularity, area and intensity of targets). It was found that the implemented approach yielded precise and accurate quantification of both oncolytic viral vaccines and gene therapy vectors in a time- and resource-effective manner when compared with conventional methodologies.

Indexed as

adenovirushexon proteinhighthroughput microscopyimmunocytochemistrymultiplicity of infectiononcolytic vaccinesvaccinesvaccines titeringvector quantificationviruses

Identifiers

PMID39968184
PMCPMC11834061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.